Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: oral hBNP - Biocon

Drug Profile

Research programme: oral hBNP - Biocon

Alternative Names: BN-054; BNP 054; NBN 002; NBN 054; NBN 054 - Biocon

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocon
  • Class Natriuretic peptides
  • Mechanism of Action Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cardiovascular disorders
  • Discontinued Heart failure

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in India (PO)
  • 26 Sep 2005 Data presented at the 9th Annual Scientific Meeting of the Heart Failure Society of America (HFSA-2005) have been added to the Heart failure pharmacodynamics section
  • 30 Aug 2005 Nobex and Biocon have entered into an agreement to co-develop oral hBNP worldwide for for the treatment of heart failure and other portential cardiovascular disease indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top